Clinical Trials at Dana-Farber Cancer Institute

As of June 2026, 362 paid clinical trials are recruiting at Dana-Farber Cancer Institute, located at Dana-Farber Cancer Institute Longwood Center, 360 Longwood Ave, Boston, MA 02215 in Boston, Massachusetts. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

362 clinical trials at Dana-Farber Cancer Institute

·Clear filters·↓ Download CSV

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

for Non-small Cell Lung Cancer

29 locations incl. Fresno

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07195695·Phase 3·Recruiting

Apply to this trial

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

for Estrogen-receptor-positive Breast Cancer

1 location in Boston

Sponsor: Kristina A. Fanucci

Sex: All·Age: 18+

Code: NCT07222215·Phase 2·Recruiting

Apply to this trial

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

for Renal Cell Carcinoma

Drug: BMS-986506

5 locations incl. Boston

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07195682·Phase 1·Recruiting

Apply to this trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Drug: Navlimetostat

42 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07063745·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

117 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting

Apply to this trial

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

for Relapsed Refractory Multiple Myeloma (RRMM)

Drug: Mezigdomide

3 locations incl. Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT07032714·Phase 1·Recruiting

Apply to this trial

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

for Advanced Solid Tumors

4 locations incl. Boston

Sponsor: Ottimo Pharma Limited

Sex: All·Age: 18+

Code: NCT07266428·Phase 1, Phase 2·Recruiting

Apply to this trial

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

for Advanced Or Metastatic Merkel Cell Carcinoma

18 locations incl. Los Angeles

Sponsor: TuHURA Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT06947928·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

Drug: Atezolizumab

9 locations incl. New Haven

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07155174·Phase 2·Recruiting

Apply to this trial

Mosunetuzumab for CLL MRD Clearance

for Leukemia

Drug: Mosunetuzumab

2 locations incl. Boston

Sponsor: Inhye Ahn

Sex: All·Age: 18+

Code: NCT07052695·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

for Metastatic Renal Cell Carcinoma

2 locations incl. Boston

Sponsor: Stephanie Berg

Sex: All·Age: 18+

Code: NCT07123090·Phase 2·Recruiting

Apply to this trial

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

for Endometrial Cancer

1 location in Boston

Sponsor: Jessica D. St. Laurent, MD

Sex: Female·Age: 18+·Accepts healthy volunteers

Code: NCT07220239·Recruiting

Apply to this trial

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

for Metastatic Breast Cancer

1 location in Boston

Sponsor: Kristina A. Fanucci

Sex: All·Age: 18+

Code: NCT07198724·Phase 1, Phase 2·Recruiting

Apply to this trial

Germline Testing for Predisposition to Myeloid Malignancies

for Myeloid Malignancy

1 location in Boston

Sponsor: Christopher Reilly

Sex: All·Age: 18+

Code: NCT07112287·Recruiting

Apply to this trial

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

for Lymphoma

14 locations incl. Aurora

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT07015242·Phase 2·Recruiting

Apply to this trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

for Non-Small Cell Lung Cancer

28 locations incl. Irvine

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07100080·Phase 2, Phase 3·Recruiting

Apply to this trial

ACT Lung Health Intervention: Phase Two

for Smoking Cessation

2 locations incl. Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18 - 100·Accepts healthy volunteers

Code: NCT06945120·Recruiting

Apply to this trial

Cryocompression for CIPN

for Chemotherapy-induced Peripheral Neuropathy

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT07064798·Recruiting

Apply to this trial

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

for Small-cell Lung Cancer

20 locations incl. Denver

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07174583·Phase 1, Phase 2·Recruiting

Apply to this trial

Circulating Tumor DNA

for ER+ Breast Cancer

7 locations incl. New Haven

Sponsor: Yale University

Sex: All·Age: 18+

Code: NCT06923527·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

for Small Cell Lung Cancer ( SCLC )

1 location in Boston

Sponsor: Addario Lung Cancer Medical Institute

Sex: All·Age: 18+

Code: NCT07075627·Not Yet Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

for KRAS Mutant Solid Tumors

6 locations incl. Birmingham

Sponsor: Treeline Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07204340·Phase 1·Recruiting

Apply to this trial

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

9 locations incl. Stanford

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07111520·Phase 1, Phase 2·Recruiting

Apply to this trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for Anatomic Stage I Breast Cancer AJCC v8

652 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06876714·Phase 3·Recruiting

Apply to this trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

for Extensive Stage Small Cell Lung Cancer

Drug: Tarlatamab

13 locations incl. Gilbert

Sponsor: Amgen

Sex: All·Age: 18 - 90

Code: NCT07037758·Phase 1·Recruiting

Apply to this trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for Breast Neoplasms

46 locations incl. Hot Springs

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06926868·Phase 2, Phase 3·Recruiting

Apply to this trial

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

for Breast Cancer

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: Female·Age: 80+·Accepts healthy volunteers

Code: NCT07123649·Phase 2·Recruiting

Apply to this trial

HEME Home Transfusion Program

for Leukemia

2 locations incl. Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06487247·Recruiting

Apply to this trial

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

for Carcinoma, Non-Small-Cell Lung

Drug: Navlimetostat

12 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06855771·Phase 2·Recruiting

Apply to this trial

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

for Renal Cell Carcinoma

5 locations incl. Boston

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT06966024·Phase 1·Recruiting

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

21 locations incl. Duarte

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07090499·Phase 1·Recruiting

Apply to this trial

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

for Acute Myeloid Leukemia

22 locations incl. New Haven

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06484062·Phase 1·Recruiting

Apply to this trial

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

for Chronic Graft Versus Host Disease

3 locations incl. Tampa

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18+

Code: NCT07011810·Phase 2·Recruiting

Apply to this trial

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

for Breast Neoplasms

16 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07114601·Phase 1·Recruiting

Apply to this trial

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

for High Grade Glioma

10 locations incl. Aurora

Sponsor: Nationwide Children's Hospital

Sex: All·Age: 1 - 21·Accepts healthy volunteers

Code: NCT06333899·EARLY_Phase 1·Recruiting

Apply to this trial

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

for Advanced Solid Tumor

15 locations incl. Birmingham

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06997029·Phase 1·Recruiting

Apply to this trial

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

for AML (Acute Myelogenous Leukemia)

13 locations incl. Birmingham

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: 18 - 66

Code: NCT06859424·Phase 2·Recruiting

Apply to this trial

Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study

for Cancer Survivorship

2 locations incl. Miami

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06623097·Recruiting

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

for Multiple Myeloma

10 locations incl. Los Angeles

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06953960·Phase 1, Phase 2·Recruiting

Apply to this trial

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

for Non-small Cell Lung Cancer

22 locations incl. Glendale

Sponsor: Nuvalent Inc.

Sex: All·Age: 18+

Code: NCT06765109·Phase 3·Recruiting

Apply to this trial